Subscribe

Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs

Value-Based Care in Myeloma - Multiple Myeloma
Caroline Helwick

Instituting guidelines-based test ordering could lead to more effective, accurate, and complete diagnosis and monitoring of hemato­lymphoid malignancies, while reduc­ing costs, according to hematopatho­lo­gists at Vanderbilt Univer­sity Medical Center, Nashville, who said that tests were frequently overordered by their hematologists.

Molecular and cytogenetic testing is critical in the diagnosis and management of hematologic malignancies, but these can be complex and expensive. No comprehensive guidelines exist for the disease- and patient-specific selection of these tests.

The Hematopathology Diagnostic Management Team explored the hypothesis that there is significant variability in test-ordering patterns, including overordering of unnecessary tests and underordering of necessary tests. They established evidence-based standard operating procedures for molecular and cytogenetic test ordering, which pathologists would apply after a review of the patient’s clinical history and bone marrow morphology. These standards were then compared with current practices at Vanderbilt.

“We found that if we followed the guidelines in all cases, and eliminated excess testing, we would save our payers $1.25 million a year,” said Adam C. Seegmiller, MD, PhD, a hematopathologist who led this study.

“Before we instituted this, we found that clinicians had a tendency to overorder tests, when doing molecular cytogenetic testing before the bone marrow biopsy was done,” Dr Seegmiller said. “We created a standard operating procedure based on current guidelines, best evidence, and best clinical practice. We decided what tests should be ordered for 6 categories of disease and their stages. It’s a very simple chart.”

They evaluated 3007 ordered tests on 804 bone marrow biopsy specimens; this included 769 karyotypes, 1790 fluorescence in situ hybridization assays, and 448 molecular tests. Comparing how clinicians ordered (or did not order) tests with this new standard operating procedure showed that:

  • Only 1927 tests (64%) were concordant with the new guidelines
  • 1080 tests (36%) were discordant
  • 307 tests were omitted that would have been recommended by the new guidelines.

“Over one third were tests that the guidelines would not have recommended [ie, overordered], while 307 tests should have been ordered but were not,” Dr Seegmiller noted.

By stage and clinical scenario, for example, there was 99% concordance between clinicians’ ordering and guidelines for the diagnosis of myeloma, but 0% concordance for testing during follow-up, and 0% posttransplant. For lymphoma, concordance was 81% for diagnosis, 41% for staging, 13% for follow-up, 70% pretransplant, and 32% posttransplant.

“Among discordant tests, only 4% came back positive [ie, detected a mutation], but more than one third of these were redundant. They were positive, but we would have caught these cases elsewhere,” he said. Only 1% of cases were true positives that would have been missed.

“We think we are not only eliminating unnecessary tests, but also increasing the effectiveness of the tests we are using,” Dr Seegmiller added.

“We have now given hematologists the option to turn over all the testing decisions to the hematopathologists, and about 80% of the time our clinicians do that,” he said. Using this new standard, “the hematopathologist makes a decision for testing based on the patient’s clinical history, the appearance of the bone marrow morphology, and the guidelines.”
 

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives published on March 31, 2017 in Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
Dana Taylor
VBCC - February 2016, Vol 7, No 1 published on February 16, 2016 in Multiple Myeloma
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
VBCC - February 2016, Vol 7, No 1 published on February 16, 2016 in Multiple Myeloma
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
VBCC - February 2016, Vol 7, No 1 published on February 16, 2016 in Multiple Myeloma
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
VBCC - February 2016, Vol 7, No 1 published on February 16, 2016 in Multiple Myeloma
Last modified: May 20, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology